Kim MJ, Nasr A, Kabir B, de Nanassy J, Tang K, Menzies-Toman D, Johnston D, El Demellawy D (October 2017). "Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm: A Systematic Literature Review". Journal of Pediatric Hematology/Oncology. 39 (7): 528–537. doi:10.1097/MPH.0000000000000964. PMID28906324. S2CID11799428.
Pemmaraju N (December 2017). "Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond". Current Hematologic Malignancy Reports. 12 (6): 510–512. doi:10.1007/s11899-017-0425-7. PMID29064022. S2CID207330989.
Wang S, Wang X, Liu M, Bai O (April 2018). "Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel agents". Annals of Hematology. 97 (4): 563–572. doi:10.1007/s00277-018-3259-z. PMID29455234. S2CID3627886.
Sumarriva Lezama L, Chisholm KM, Carneal E, Nagy A, Cascio MJ, Yan J, Chang CC, Cherry A, George TI, Ohgami RS (June 2018). "An analysis of blastic plasmacytoid dendritic cell neoplasm with translocations involving the MYC locus identifies t(6;8)(p21;q24) as a recurrent cytogenetic abnormality". Histopathology. 73 (5): 767–776. doi:10.1111/his.13668. PMID29884995. S2CID47003308.
Suma S, Sakata-Yanagimoto M, Nguyen TB, Hattori K, Sato T, Noguchi M, Nannya Y, Ogawa S, Watanabe R, Fujimoto M, Nakamura N, Kusakabe M, Nishikii H, Kato T, Chiba S (April 2018). "Blastic plasmacytoid dendritic cell neoplasm arising from clonal hematopoiesis". International Journal of Hematology. 108 (4): 447–451. doi:10.1007/s12185-018-2461-z. PMID29705980. S2CID13993911.
Tandon, a.; Zhang, y.; Sokol, l. (2019). "Tagraxofusp, a novel CD123-directed cytotoxin to treat blastic plasmacytoid dendritic cell neoplasm". Drugs of Today. 55 (12). Portico: 735–742. doi:10.1358/dot.2019.55.12.3058917. ISSN1699-4019. PMID31942876.
Kim MJ, Nasr A, Kabir B, de Nanassy J, Tang K, Menzies-Toman D, Johnston D, El Demellawy D (October 2017). "Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm: A Systematic Literature Review". Journal of Pediatric Hematology/Oncology. 39 (7): 528–537. doi:10.1097/MPH.0000000000000964. PMID28906324. S2CID11799428.
Pemmaraju N (December 2017). "Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond". Current Hematologic Malignancy Reports. 12 (6): 510–512. doi:10.1007/s11899-017-0425-7. PMID29064022. S2CID207330989.
Wang S, Wang X, Liu M, Bai O (April 2018). "Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel agents". Annals of Hematology. 97 (4): 563–572. doi:10.1007/s00277-018-3259-z. PMID29455234. S2CID3627886.
Sumarriva Lezama L, Chisholm KM, Carneal E, Nagy A, Cascio MJ, Yan J, Chang CC, Cherry A, George TI, Ohgami RS (June 2018). "An analysis of blastic plasmacytoid dendritic cell neoplasm with translocations involving the MYC locus identifies t(6;8)(p21;q24) as a recurrent cytogenetic abnormality". Histopathology. 73 (5): 767–776. doi:10.1111/his.13668. PMID29884995. S2CID47003308.
Suma S, Sakata-Yanagimoto M, Nguyen TB, Hattori K, Sato T, Noguchi M, Nannya Y, Ogawa S, Watanabe R, Fujimoto M, Nakamura N, Kusakabe M, Nishikii H, Kato T, Chiba S (April 2018). "Blastic plasmacytoid dendritic cell neoplasm arising from clonal hematopoiesis". International Journal of Hematology. 108 (4): 447–451. doi:10.1007/s12185-018-2461-z. PMID29705980. S2CID13993911.
Tandon, a.; Zhang, y.; Sokol, l. (2019). "Tagraxofusp, a novel CD123-directed cytotoxin to treat blastic plasmacytoid dendritic cell neoplasm". Drugs of Today. 55 (12). Portico: 735–742. doi:10.1358/dot.2019.55.12.3058917. ISSN1699-4019. PMID31942876.
Kim MJ, Nasr A, Kabir B, de Nanassy J, Tang K, Menzies-Toman D, Johnston D, El Demellawy D (October 2017). "Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm: A Systematic Literature Review". Journal of Pediatric Hematology/Oncology. 39 (7): 528–537. doi:10.1097/MPH.0000000000000964. PMID28906324. S2CID11799428.
Pemmaraju N (December 2017). "Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond". Current Hematologic Malignancy Reports. 12 (6): 510–512. doi:10.1007/s11899-017-0425-7. PMID29064022. S2CID207330989.
Wang S, Wang X, Liu M, Bai O (April 2018). "Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel agents". Annals of Hematology. 97 (4): 563–572. doi:10.1007/s00277-018-3259-z. PMID29455234. S2CID3627886.
Sumarriva Lezama L, Chisholm KM, Carneal E, Nagy A, Cascio MJ, Yan J, Chang CC, Cherry A, George TI, Ohgami RS (June 2018). "An analysis of blastic plasmacytoid dendritic cell neoplasm with translocations involving the MYC locus identifies t(6;8)(p21;q24) as a recurrent cytogenetic abnormality". Histopathology. 73 (5): 767–776. doi:10.1111/his.13668. PMID29884995. S2CID47003308.
Suma S, Sakata-Yanagimoto M, Nguyen TB, Hattori K, Sato T, Noguchi M, Nannya Y, Ogawa S, Watanabe R, Fujimoto M, Nakamura N, Kusakabe M, Nishikii H, Kato T, Chiba S (April 2018). "Blastic plasmacytoid dendritic cell neoplasm arising from clonal hematopoiesis". International Journal of Hematology. 108 (4): 447–451. doi:10.1007/s12185-018-2461-z. PMID29705980. S2CID13993911.
worldcat.org
search.worldcat.org
Tandon, a.; Zhang, y.; Sokol, l. (2019). "Tagraxofusp, a novel CD123-directed cytotoxin to treat blastic plasmacytoid dendritic cell neoplasm". Drugs of Today. 55 (12). Portico: 735–742. doi:10.1358/dot.2019.55.12.3058917. ISSN1699-4019. PMID31942876.